ID   AGRIN_RAT               Reviewed;        1959 AA.
AC   P25304; Q63034;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 2.
DT   02-OCT-2024, entry version 200.
DE   RecName: Full=Agrin;
DE   Contains:
DE     RecName: Full=Agrin N-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 90 kDa fragment;
DE              Short=C90;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 22 kDa fragment;
DE              Short=C22;
GN   Name=Agrn; Synonyms=Agrin;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Embryonic spinal cord;
RX   PubMed=1851019; DOI=10.1016/0896-6273(91)90177-2;
RA   Rupp F., Payan D.G., Magill-Solc C., Cowan D.M., Scheller R.H.;
RT   "Structure and expression of a rat agrin.";
RL   Neuron 6:811-823(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5), AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=1326608; DOI=10.1523/jneurosci.12-09-03535.1992;
RA   Rupp F., Oezcelik T., Linial M., Peterson K., Francke U., Scheller R.H.;
RT   "Structure and chromosomal localization of the mammalian agrin gene.";
RL   J. Neurosci. 12:3535-3544(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-60 (ISOFORM 1), ALTERNATIVE PROMOTER USAGE,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=11161480; DOI=10.1006/mcne.2000.0932;
RA   Neumann F.R., Bittcher G., Annies M., Schumacher B., Kroger S., Ruegg M.A.;
RT   "An alternative amino-terminus expressed in the central nervous system
RT   converts agrin to a type II transmembrane protein.";
RL   Mol. Cell. Neurosci. 17:208-225(2001).
RN   [4]
RP   ALTERNATING SPLICING, TISSUE SPECIFICITY, GLYCOSYLATION, AND FUNCTION.
RX   PubMed=8398142; DOI=10.1016/0896-6273(93)90153-i;
RA   Ferns M.J., Campanelli J.T., Hoch W., Scheller R.H., Hall Z.;
RT   "The ability of agrin to cluster AChRs depends on alternative splicing and
RT   on cell surface proteoglycans.";
RL   Neuron 11:491-502(1993).
RN   [5]
RP   ALTERNATIVE SPLICING, AND DEVELOPMENTAL STAGE.
RX   PubMed=7472435; DOI=10.1523/jneurosci.15-10-06767.1995;
RA   Stone D.M., Nikolics K.;
RT   "Tissue- and age-specific expression patterns of alternatively spliced
RT   agrin mRNA transcripts in embryonic rat suggest novel developmental
RT   roles.";
RL   J. Neurosci. 15:6767-6778(1995).
RN   [6]
RP   FUNCTION IN NEUROMUSCULAR JUNCTION DEVELOPMENT, SUBCELLULAR LOCATION,
RP   FUNCTION IN PHOSPHORYLATION OF MUSK, AND INTERACTION WITH LRP4.
RX   PubMed=8653787; DOI=10.1016/s0092-8674(00)81252-0;
RA   Glass D.J., Bowen D.C., Stitt T.N., Radziejewski C., Bruno J., Ryan T.E.,
RA   Gies D.R., Shah S., Mattsson K., Burden S.J., DiStefano P.S.,
RA   Valenzuela D.M., DeChiara T.M., Yancopoulos G.D.;
RT   "Agrin acts via a MuSK receptor complex.";
RL   Cell 85:513-523(1996).
RN   [7]
RP   ALTERNATIVE SPLICING, INTERACTION WITH DAG1, HEPARIN BINDING, AND FUNCTION.
RX   PubMed=8693000; DOI=10.1073/pnas.93.14.7369;
RA   O'Toole J.J., Deyst K.A., Bowe M.A., Nastuk M.A., McKechnie B.A.,
RA   Fallon J.R.;
RT   "Alternative splicing of agrin regulates its binding to heparin, alpha-
RT   dystroglycan, and the cell surface.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7369-7374(1996).
RN   [8]
RP   PROTEOLYTIC PROCESSING, IDENTIFICATION OF PROTEOLYTICALLY CLEAVED PRODUCTS
RP   BY MASS SPECTROMETRY, AND MUTAGENESIS OF PRO-991; PRO-992; ILE-993;
RP   GLU-994; ARG-995; LEU-1751; VAL-1752; GLU-1753; LYS-1754; SER-1755;
RP   VAL-1756 AND GLY-1757.
RX   PubMed=17586728; DOI=10.1096/fj.07-8800com;
RA   Reif R., Sales S., Hettwer S., Dreier B., Gisler C., Wolfel J., Luscher D.,
RA   Zurlinden A., Stephan A., Ahmed S., Baici A., Ledermann B., Kunz B.,
RA   Sonderegger P.;
RT   "Specific cleavage of agrin by neurotrypsin, a synaptic protease linked to
RT   mental retardation.";
RL   FASEB J. 21:3468-3478(2007).
RN   [9]
RP   GLYCOSYLATION AT SER-1726, FUNCTION, AND MUTAGENESIS OF SER-1726.
RX   PubMed=18775496; DOI=10.1016/j.mcn.2008.07.026;
RA   Kim M.L., Chandrasekharan K., Glass M., Shi S., Stahl M.C., Kaspar B.,
RA   Stanley P., Martin P.T.;
RT   "O-fucosylation of muscle agrin determines its ability to cluster
RT   acetylcholine receptors.";
RL   Mol. Cell. Neurosci. 39:452-464(2008).
RN   [10]
RP   FUNCTION.
RX   PubMed=19524020; DOI=10.1016/j.neuroscience.2009.06.012;
RA   McCroskery S., Bailey A., Lin L., Daniels M.P.;
RT   "Transmembrane agrin regulates dendritic filopodia and synapse formation in
RT   mature hippocampal neuron cultures.";
RL   Neuroscience 163:168-179(2009).
RN   [11]
RP   FUNCTION, HEPARAN SULFATE BINDING, AND CHONDROITIN SULFATE BINDING.
RX   PubMed=20471381; DOI=10.1016/j.yexcr.2010.05.006;
RA   Lin L., McCroskery S., Ross J.M., Chak Y., Neuhuber B., Daniels M.P.;
RT   "Induction of filopodia-like protrusions by transmembrane agrin: role of
RT   agrin glycosaminoglycan chains and Rho-family GTPases.";
RL   Exp. Cell Res. 316:2260-2277(2010).
RN   [12]
RP   FUNCTION, CALCIUM-BINDING, AND MUTAGENESIS OF GLU-1780; LEU-1781; THR-1782;
RP   ASN-1783; GLU-1784; ILE-1785; PRO-1786; ASP-1831 AND ASP-1900.
RX   PubMed=20566625; DOI=10.1074/jbc.m110.130625;
RA   Tseng C.N., Zhang L., Wu S.L., Wang W.F., Wang Z.Z., Cascio M.;
RT   "Asparagine of z8 insert is critical for the affinity, conformation, and
RT   acetylcholine receptor-clustering activity of neural agrin.";
RL   J. Biol. Chem. 285:27641-27651(2010).
RN   [13]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=20980386; DOI=10.1242/jcs.072090;
RA   Bolliger M.F., Zurlinden A., Luscher D., Butikofer L., Shakhova O.,
RA   Francolini M., Kozlov S.V., Cinelli P., Stephan A., Kistler A.D.,
RA   Rulicke T., Pelczar P., Ledermann B., Fumagalli G., Gloor S.M., Kunz B.,
RA   Sonderegger P.;
RT   "Specific proteolytic cleavage of agrin regulates maturation of the
RT   neuromuscular junction.";
RL   J. Cell Sci. 123:3944-3955(2010).
RN   [14]
RP   INTERACTION WITH BMP2; BMP4 AND TGFB1, AND FUNCTION.
RX   PubMed=20505824; DOI=10.1371/journal.pone.0010758;
RA   Banyai L., Sonderegger P., Patthy L.;
RT   "Agrin binds BMP2, BMP4 and TGFbeta1.";
RL   PLoS ONE 5:E10758-E10758(2010).
RN   [15] {ECO:0007744|PDB:3V64, ECO:0007744|PDB:3V65}
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 1759-1959 IN COMPLEX WITH LRP4
RP   AND CALCIUM, SUBUNIT, AND MUTAGENESIS OF ASN-1783; ILE-1785; HIS-1806;
RP   ARG-1876 AND HIS-1938.
RX   PubMed=22302937; DOI=10.1101/gad.180885.111;
RA   Zong Y., Zhang B., Gu S., Lee K., Zhou J., Yao G., Figueiredo D., Perry K.,
RA   Mei L., Jin R.;
RT   "Structural basis of agrin-LRP4-MuSK signaling.";
RL   Genes Dev. 26:247-258(2012).
CC   -!- FUNCTION: [Isoform 1]: Heparan sulfate basal lamina glycoprotein that
CC       plays a central role in the formation and the maintenance of the
CC       neuromuscular junction (NMJ) and directs key events in postsynaptic
CC       differentiation. This neuron-specific (z+) isoform is a component of
CC       the AGRN-LRP4 receptor complex that induces the phosphorylation and
CC       activation of MUSK. The activation of MUSK in myotubes induces the
CC       formation of NMJ by regulating different processes including the
CC       transcription of specific genes and the clustering of AChR in the
CC       postsynaptic membrane. Calcium ions are required for maximal AChR
CC       clustering. AGRN function in neurons is highly regulated by alternative
CC       splicing, glycan binding and proteolytic processing. Modulates calcium
CC       ion homeostasis in neurons, specifically by inducing an increase in
CC       cytoplasmic calcium ions. Functions differentially in the central
CC       nervous system (CNS) by inhibiting the alpha(3)-subtype of Na+/K+-
CC       ATPase and evoking depolarization at CNS synapses. This transmembrane
CC       agrin (TM-agrin) isoform, the predominate form in neurons of the brain,
CC       induces dendritic filopodia and synapse formation in mature hippocampal
CC       neurons in large part due to the attached glycosaminoglycan chains and
CC       the action of Rho-family GTPases.
CC   -!- FUNCTION: Isoform 1, isoform 4, isoform 5 and isoform 6: neuron-
CC       specific (z+) isoforms that contain C-terminal insertions of 8-19 AA
CC       are potent activators of AChR clustering. Isoform 5, agrin (z+8),
CC       containing the 8-AA insert, forms a receptor complex in myotubules
CC       containing the neuronal AGRN, the muscle-specific kinase MUSK and LRP4,
CC       a member of the LDL receptor family. The splicing factors, NOVA1 and
CC       NOVA2, regulate AGRN splicing and production of the 'z' isoforms.
CC   -!- FUNCTION: [Agrin N-terminal 110 kDa subunit]: Is involved in regulation
CC       of neurite outgrowth probably due to the presence of the
CC       glycosaminoglcan (GAG) side chains of heparan and chondroitin sulfate
CC       attached to the Ser/Thr- and Gly/Ser-rich regions. Also involved in
CC       modulation of growth factor signaling (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:18775496, ECO:0000269|PubMed:19524020,
CC       ECO:0000269|PubMed:20471381, ECO:0000269|PubMed:20505824,
CC       ECO:0000269|PubMed:20566625, ECO:0000269|PubMed:8398142,
CC       ECO:0000269|PubMed:8653787, ECO:0000269|PubMed:8693000}.
CC   -!- FUNCTION: [Agrin C-terminal 22 kDa fragment]: This released fragment is
CC       important for agrin signaling and to exert a maximal dendritic
CC       filopodia-inducing effect. All 'z' splice variants (z+) of this
CC       fragment also show an increase in the number of filopodia.
CC   -!- SUBUNIT: Monomer. Component of the AGRN-LRP4 complex that consists of a
CC       tetramer of two AGRN-LRP4 heterodimers. Interacts (via the laminin G-
CC       like 3 domain) directly with LRP4; the interaction is required for
CC       activation of MUSK and clustering of AChR and requires the 'z8' insert
CC       present in the z(+8) isoforms. Interacts (N-terminal subunit) with TGF-
CC       beta family members, BMP2 and BMP4; the interactions inhibit the
CC       activity of these growth factors. Interacts with TGFB1; the interaction
CC       enhances the activity of TGFB1. Interacts with DAG1; the interaction is
CC       influenced by cell surface glycosaminoglycans and by alternative
CC       splicing of AGRN. {ECO:0000269|PubMed:20505824,
CC       ECO:0000269|PubMed:22302937, ECO:0000269|PubMed:8653787,
CC       ECO:0000269|PubMed:8693000}.
CC   -!- INTERACTION:
CC       P25304; Q8VI56: Lrp4; Xeno; NbExp=3; IntAct=EBI-2106099, EBI-2106160;
CC   -!- SUBCELLULAR LOCATION: Synapse {ECO:0000269|PubMed:8653787}. Cell
CC       membrane {ECO:0000269|PubMed:11161480}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:11161480}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Many isoforms exist depending on the occurrence and length of
CC         inserts at the x, y or z splice site. There are 4 'z' isoforms
CC         produced with inserts of 0, 8, 11 or 19 AA. Isoforms differ in their
CC         acetylcholine receptor clustering activity and tissue specificity. In
CC         addition, a secreted isoform may be produced by alternative usage of
CC         the first exon.;
CC       Name=1; Synonyms=Transmembrane agrin, TM-agrin, Agrin z(+19);
CC         IsoId=P25304-1; Sequence=Displayed;
CC       Name=2; Synonyms=Agrin x(0);
CC         IsoId=P25304-2; Sequence=VSP_001365;
CC       Name=3; Synonyms=Agrin z(0);
CC         IsoId=P25304-3; Sequence=VSP_001366;
CC       Name=4; Synonyms=Agrin z(+11);
CC         IsoId=P25304-4; Sequence=VSP_001367;
CC       Name=5; Synonyms=Agrin z(+8);
CC         IsoId=P25304-5; Sequence=VSP_001368;
CC       Name=6; Synonyms=Agrin y(0);
CC         IsoId=P25304-6; Sequence=VSP_045759;
CC   -!- TISSUE SPECIFICITY: Embryonic nervous system and muscle.
CC       {ECO:0000269|PubMed:1851019, ECO:0000269|PubMed:8398142}.
CC   -!- DEVELOPMENTAL STAGE: More abundant early in development. At 13 dpc,
CC       highly expressed in the developing nervous system. Isoform y(+4)z(0),
CC       containing the 'y' insert but no 'z' insert, is the most prevelant at
CC       this stage with pronounced expression in developing spinal and
CC       sympathetic ganglia. Isoforms with no 'y' insert (y0) localized to
CC       peripheral tissue. At 15 dpc, y(+4) isoform continues to be highly
CC       expressed in neural tissue predominantly in the spinal column and
CC       developing brain. The y(0) isoform is weakly expressed in capillaries
CC       and meninges and the y(0)(z0) in non-neural tissues, predominantly in
CC       epithelial cells lining the developing lung bronchioles and kidney
CC       tubules. Isoforms Z(+8) and z(+19) are highly expressed in ventral
CC       motor columns and facial nerve with weaker expression throughout spinal
CC       cord tissue. At later stages of development, isoform y(4)z(0) is the
CC       most prominent form in developing cortex, corpus striatum, hippocampus
CC       and cerebellum. Isoform y(0)z(0) expression is still detected in brain
CC       capillaries at stage P1. The z(+19) isoform is most highly expressed
CC       from 15 dpc to 18 dpc and declines slightly to P1. Isoforms y(1)4z(0)
CC       and y(+4)z(+8) are still expressed in adulthood, the former scattered
CC       throughout the spinal cord gray matter and, the latter, in motor
CC       neurons of the ventral spinal cord. {ECO:0000269|PubMed:1326608,
CC       ECO:0000269|PubMed:7472435}.
CC   -!- DOMAIN: Both laminin G-like 2 (G2) and laminin G-like 3 (G3) domains
CC       are required for alpha-dystroglycan binding. G3 domain is required for
CC       C-terminal heparin, heparan sulfate and sialic acid binding.
CC   -!- PTM: Contains heparan and chondroitin sulfate chains and alpha-
CC       dystroglycan as well as N-linked and O-linked oligosaccharides.
CC       Glycosaminoglycans (GAGs), present in the agrin N-terminal 110 kDa
CC       fragment, are required for induction of filopodia in hippocampal
CC       neurons. The first cluster (Gly/Ser-rich) for GAG attachment contains
CC       heparan sulfate (HS) chains and the second cluster (Ser/Thr-rich),
CC       contains chondroitin sulfate (CS) chains. Heparin and heparin sulfate
CC       binding in the G3 doamin is independent of calcium ions. Binds heparin
CC       with a stoichiometry of 2:1. Binds sialic acid with a stoichiometry of
CC       1:1 and binding requires calcium ions. {ECO:0000269|PubMed:18775496,
CC       ECO:0000269|PubMed:8398142}.
CC   -!- PTM: At synaptic junctions, cleaved at two conserved sites, alpha and
CC       beta, by neurotrypsin. Cleavage at the alpha-site produces the agrin N-
CC       terminal 110-kDa subunit and the agrin C-terminal 110-kDa subunit.
CC       Further cleavage of agrin C-terminal 110-kDa subunit at the beta site
CC       produces the C-terminal fragments, agrin C-terminal 90 kDa fragment and
CC       agrin C-terminal 22 kDa fragment. Excessive cleavage at the beta-site
CC       releases large amounts of the agrin C-terminal 22 kDa fragment leading
CC       to destabilization at the neuromuscular junction (NMJ).
CC       {ECO:0000269|PubMed:17586728, ECO:0000269|PubMed:20980386}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64780; AAA40702.1; -; mRNA.
DR   EMBL; M64780; AAA40703.1; -; mRNA.
DR   EMBL; S44194; AAB23326.1; -; mRNA.
DR   PIR; JH0399; AGRT.
DR   RefSeq; NP_786930.1; NM_175754.1.
DR   PDB; 3V64; X-ray; 2.85 A; A/B=1759-1959.
DR   PDB; 3V65; X-ray; 3.30 A; A/C=1759-1959.
DR   PDBsum; 3V64; -.
DR   PDBsum; 3V65; -.
DR   AlphaFoldDB; P25304; -.
DR   SMR; P25304; -.
DR   IntAct; P25304; 4.
DR   STRING; 10116.ENSRNOP00000050623; -.
DR   CarbonylDB; P25304; -.
DR   GlyCosmos; P25304; 5 sites, No reported glycans.
DR   GlyGen; P25304; 5 sites.
DR   iPTMnet; P25304; -.
DR   PhosphoSitePlus; P25304; -.
DR   SwissPalm; P25304; -.
DR   PaxDb; 10116-ENSRNOP00000050623; -.
DR   GeneID; 25592; -.
DR   KEGG; rno:25592; -.
DR   AGR; RGD:2067; -.
DR   CTD; 375790; -.
DR   RGD; 2067; Agrn.
DR   eggNOG; KOG3509; Eukaryota.
DR   InParanoid; P25304; -.
DR   OrthoDB; 2878505at2759; -.
DR   PhylomeDB; P25304; -.
DR   Reactome; R-RNO-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-RNO-2022928; HS-GAG biosynthesis.
DR   Reactome; R-RNO-2024096; HS-GAG degradation.
DR   Reactome; R-RNO-3000178; ECM proteoglycans.
DR   Reactome; R-RNO-975634; Retinoid metabolism and transport.
DR   EvolutionaryTrace; P25304; -.
DR   PRO; PR:P25304; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0044295; C:axonal growth cone; IDA:RGD.
DR   GO; GO:0005604; C:basement membrane; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; ISO:RGD.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0042383; C:sarcolemma; ISO:RGD.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0043083; C:synaptic cleft; ISO:RGD.
DR   GO; GO:0030548; F:acetylcholine receptor regulator activity; ISO:RGD.
DR   GO; GO:0042030; F:ATPase inhibitor activity; ISO:RGD.
DR   GO; GO:0036122; F:BMP binding; IPI:RGD.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0035374; F:chondroitin sulfate binding; ISS:UniProtKB.
DR   GO; GO:0002162; F:dystroglycan binding; IDA:UniProtKB.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0048018; F:receptor ligand activity; ISO:RGD.
DR   GO; GO:0033691; F:sialic acid binding; ISS:UniProtKB.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:RGD.
DR   GO; GO:0044325; F:transmembrane transporter binding; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007268; P:chemical synaptic transmission; IMP:RGD.
DR   GO; GO:0007623; P:circadian rhythm; ISO:RGD.
DR   GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; ISO:RGD.
DR   GO; GO:0097049; P:motor neuron apoptotic process; ISO:RGD.
DR   GO; GO:1903277; P:negative regulation of sodium ion export across plasma membrane; ISO:RGD.
DR   GO; GO:0007528; P:neuromuscular junction development; ISO:RGD.
DR   GO; GO:0007009; P:plasma membrane organization; ISO:RGD.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:2000673; P:positive regulation of motor neuron apoptotic process; ISO:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000541; P:positive regulation of protein geranylgeranylation; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0035022; P:positive regulation of Rac protein signal transduction; ISO:RGD.
DR   GO; GO:1904395; P:positive regulation of skeletal muscle acetylcholine-gated channel clustering; ISO:RGD.
DR   GO; GO:0045887; P:positive regulation of synaptic assembly at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0015031; P:protein transport; ISO:RGD.
DR   GO; GO:0043113; P:receptor clustering; IDA:MGI.
DR   GO; GO:1902667; P:regulation of axon guidance; IDA:RGD.
DR   GO; GO:0086036; P:regulation of cardiac muscle cell membrane potential; ISO:RGD.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; ISO:RGD.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:RGD.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050807; P:regulation of synapse organization; IDA:SynGO.
DR   GO; GO:0060025; P:regulation of synaptic activity; ISO:RGD.
DR   GO; GO:0071340; P:skeletal muscle acetylcholine-gated channel clustering; IDA:UniProtKB.
DR   GO; GO:0007416; P:synapse assembly; IMP:RGD.
DR   CDD; cd00054; EGF_CA; 1.
DR   CDD; cd00055; EGF_Lam; 2.
DR   CDD; cd00104; KAZAL_FS; 9.
DR   CDD; cd00110; LamG; 3.
DR   Gene3D; 2.60.120.200; -; 3.
DR   Gene3D; 3.30.60.30; -; 9.
DR   Gene3D; 2.10.25.10; Laminin; 6.
DR   Gene3D; 3.30.70.960; SEA domain; 1.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003884; FacI_MAC.
DR   InterPro; IPR003645; Fol_N.
DR   InterPro; IPR002350; Kazal_dom.
DR   InterPro; IPR036058; Kazal_dom_sf.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR002049; LE_dom.
DR   InterPro; IPR050372; Neurexin-related_CASP.
DR   InterPro; IPR000082; SEA_dom.
DR   InterPro; IPR036364; SEA_dom_sf.
DR   PANTHER; PTHR15036:SF83; AGRIN; 1.
DR   PANTHER; PTHR15036; PIKACHURIN-LIKE PROTEIN; 1.
DR   Pfam; PF00008; EGF; 3.
DR   Pfam; PF00050; Kazal_1; 1.
DR   Pfam; PF07648; Kazal_2; 8.
DR   Pfam; PF00053; Laminin_EGF; 2.
DR   Pfam; PF00054; Laminin_G_1; 3.
DR   Pfam; PF01390; SEA; 1.
DR   PRINTS; PR00011; EGFLAMININ.
DR   SMART; SM00181; EGF; 6.
DR   SMART; SM00179; EGF_CA; 3.
DR   SMART; SM00180; EGF_Lam; 2.
DR   SMART; SM00057; FIMAC; 3.
DR   SMART; SM00274; FOLN; 5.
DR   SMART; SM00280; KAZAL; 9.
DR   SMART; SM00282; LamG; 3.
DR   SMART; SM00200; SEA; 1.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 3.
DR   SUPFAM; SSF57196; EGF/Laminin; 3.
DR   SUPFAM; SSF100895; Kazal-type serine protease inhibitors; 9.
DR   SUPFAM; SSF82671; SEA domain; 1.
DR   PROSITE; PS00022; EGF_1; 6.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01248; EGF_LAM_1; 1.
DR   PROSITE; PS50027; EGF_LAM_2; 2.
DR   PROSITE; PS51465; KAZAL_2; 9.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 3.
DR   PROSITE; PS50024; SEA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Developmental protein; Differentiation; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Heparan sulfate; Laminin EGF-like domain; Membrane;
KW   Metal-binding; Phosphoprotein; Proteoglycan; Reference proteome; Repeat;
KW   Signal-anchor; Synapse; Transmembrane; Transmembrane helix.
FT   CHAIN           1..1959
FT                   /note="Agrin"
FT                   /id="PRO_0000007472"
FT   CHAIN           27..995
FT                   /note="Agrin N-terminal 110 kDa subunit"
FT                   /id="PRO_0000421621"
FT   CHAIN           996..1959
FT                   /note="Agrin C-terminal 110 kDa subunit"
FT                   /id="PRO_0000421622"
FT   CHAIN           996..1754
FT                   /note="Agrin C-terminal 90 kDa fragment"
FT                   /id="PRO_0000421623"
FT   CHAIN           1755..1959
FT                   /note="Agrin C-terminal 22 kDa fragment"
FT                   /id="PRO_0000421624"
FT   TOPO_DOM        1..26
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        27..47
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        48..1959
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          86..139
FT                   /note="Kazal-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          159..214
FT                   /note="Kazal-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          232..286
FT                   /note="Kazal-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          303..358
FT                   /note="Kazal-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          379..431
FT                   /note="Kazal-like 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          442..496
FT                   /note="Kazal-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          502..561
FT                   /note="Kazal-like 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          594..647
FT                   /note="Kazal-like 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          688..741
FT                   /note="Laminin EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00460"
FT   DOMAIN          742..788
FT                   /note="Laminin EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00460"
FT   DOMAIN          810..866
FT                   /note="Kazal-like 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          1023..1145
FT                   /note="SEA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00188"
FT   DOMAIN          1220..1258
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1263..1439
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          1440..1477
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1479..1516
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1526..1708
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          1709..1748
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1784..1956
FT                   /note="Laminin G-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   REGION          951..980
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1173..1228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         1831
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0007744|PDB:3V64, ECO:0007744|PDB:3V65"
FT   BINDING         1848
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0007744|PDB:3V64, ECO:0007744|PDB:3V65"
FT   BINDING         1898
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0007744|PDB:3V64, ECO:0007744|PDB:3V65"
FT   BINDING         1900
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0007744|PDB:3V64"
FT   SITE            995..996
FT                   /note="Cleavage, alpha site; by neurotrypsin"
FT   SITE            1143
FT                   /note="Alternative splice site to produce 'x' isoforms"
FT   SITE            1642
FT                   /note="Alternative splice site to produce 'y' isoforms"
FT   SITE            1753
FT                   /note="Critical for cleavage by neurotrypsin"
FT   SITE            1754..1755
FT                   /note="Cleavage, beta site; by neurotrypsin"
FT   SITE            1779
FT                   /note="Alternative splice site to produce 'z' isoforms"
FT   SITE            1783
FT                   /note="Highly important for the agrin receptor complex
FT                   activity of the 'z(8)' insert"
FT   MOD_RES         569
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2ASQ1"
FT   MOD_RES         571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2ASQ1"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        672
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        827
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        957
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1726
FT                   /note="O-linked (Fuc...) serine"
FT                   /evidence="ECO:0000269|PubMed:18775496"
FT   DISULFID        92..123
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        97..116
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        105..137
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        165..198
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        171..191
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        180..212
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        244..263
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        252..284
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        309..342
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        316..335
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        324..356
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        385..415
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        389..408
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        397..429
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        448..480
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        454..473
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        462..494
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        508..545
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        518..538
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        527..559
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        600..631
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        604..624
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        613..645
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        688..700
FT                   /evidence="ECO:0000250"
FT   DISULFID        690..707
FT                   /evidence="ECO:0000250"
FT   DISULFID        709..718
FT                   /evidence="ECO:0000250"
FT   DISULFID        721..739
FT                   /evidence="ECO:0000250"
FT   DISULFID        742..754
FT                   /evidence="ECO:0000250"
FT   DISULFID        744..761
FT                   /evidence="ECO:0000250"
FT   DISULFID        763..772
FT                   /evidence="ECO:0000250"
FT   DISULFID        775..786
FT                   /evidence="ECO:0000250"
FT   DISULFID        816..850
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        823..843
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        832..864
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        1224..1235
FT                   /evidence="ECO:0000250"
FT   DISULFID        1229..1246
FT                   /evidence="ECO:0000250"
FT   DISULFID        1248..1257
FT                   /evidence="ECO:0000250"
FT   DISULFID        1410..1439
FT                   /evidence="ECO:0000250"
FT   DISULFID        1483..1494
FT                   /evidence="ECO:0000250"
FT   DISULFID        1488..1504
FT                   /evidence="ECO:0000250"
FT   DISULFID        1506..1515
FT                   /evidence="ECO:0000250"
FT   DISULFID        1713..1727
FT                   /evidence="ECO:0000250"
FT   DISULFID        1721..1736
FT                   /evidence="ECO:0000250"
FT   DISULFID        1738..1747
FT                   /evidence="ECO:0000250"
FT   DISULFID        1930..1956
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1144..1152
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1326608"
FT                   /id="VSP_001365"
FT   VAR_SEQ         1643..1646
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045759"
FT   VAR_SEQ         1780..1798
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1326608,
FT                   ECO:0000303|PubMed:1851019"
FT                   /id="VSP_001366"
FT   VAR_SEQ         1780..1787
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:1326608"
FT                   /id="VSP_001368"
FT   VAR_SEQ         1788..1798
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:1326608"
FT                   /id="VSP_001367"
FT   MUTAGEN         566..571
FT                   /note="SGGSGS->AGGAGA: Abolishes heparan sulfate (HS)
FT                   binding, greatly reduced branched retraction fiber (BRF)
FT                   formation, filopodia formation reduced by about 50% and
FT                   lowered RAC1 and CDK1 activation. No chondroitin sulfate
FT                   (CS) nor heparan sulfate attachment, almost no branched
FT                   retraction fiber (BRF) formation, filopodia formation
FT                   reduced by about 60% and lowered RAC1 and CDK1 activation;
FT                   when associated with 953-AGA-955."
FT   MUTAGEN         953..955
FT                   /note="SGS->AGA: Abolishes chondroitin sulfate (CS)
FT                   binding, greatly reduced branched retraction fiber (BRF)
FT                   formation, filopodia formation reduced by about 50% and
FT                   lowered RAC1 and CDK1 activation. No chondroitin sulfate
FT                   (CS) nor heparan sulfate (HS) binding almost no retraction
FT                   fiber (BRF) formation, filopodia formation reduced by about
FT                   60% lowered RAC1 and CDK1 activation; when associated with
FT                   566-AGGAGA-571."
FT   MUTAGEN         991
FT                   /note="P->A: About 13% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         992
FT                   /note="P->A: About 64% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         993
FT                   /note="I->A: About 60% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         994
FT                   /note="E->A: Almost completely abolishes cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         995
FT                   /note="R->A: Completely abolishes cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         995
FT                   /note="R->K: About 30% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1726
FT                   /note="S->A: Abolishes fucosylation of muscle agrin.
FT                   Stimulates MUSK phosphorylation and increases AChR
FT                   clustering."
FT                   /evidence="ECO:0000269|PubMed:18775496"
FT   MUTAGEN         1751
FT                   /note="L->A: About 23% reduction in cleavage by
FT                   neurotrypsin. Reduces cleavage by neurotrypsin by about
FT                   90%; when associated with A-1752. Completely abolishes
FT                   cleavage by neurotrypsin; when associated with A-1753."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1752
FT                   /note="V->A: About 41% reduction in cleavage by
FT                   neurotrypsin. Reduces cleavage by neurotrypsin by about
FT                   90%; when associated with A-1751. Completely abolishes
FT                   cleavage by neurotrypsin; when associated with A-1753."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1753
FT                   /note="E->A,K: Almost completely abolishes cleavage by
FT                   neurotrypsin. Completely abolishes cleavage by
FT                   neurotrypsin; when associated with A-1751 or A-1752."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1753
FT                   /note="E->D,L,Q: About 20% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1754
FT                   /note="K->A: Completely abolishes cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1754
FT                   /note="K->R: About 55% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1755
FT                   /note="S->A: About 62% reduction in cleavage by
FT                   neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1756
FT                   /note="V->A: Slight reduction in cleavage by neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1757
FT                   /note="G->A: Slight reduction in cleavage by neurotrypsin."
FT                   /evidence="ECO:0000269|PubMed:17586728"
FT   MUTAGEN         1780
FT                   /note="E->A: Slight reduction in AChR clustering ability."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1781
FT                   /note="L->A: Slight reduction in AChR clustering ability.
FT                   Slight reduction in AChR clustering ability."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1782
FT                   /note="T->A: Slight reduction in AChR clustering ability."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1783
FT                   /note="N->A: Abolishes formation of AGRN-LRP4 complex and
FT                   MUSK activation. No AChR clustering activity."
FT                   /evidence="ECO:0000269|PubMed:20566625,
FT                   ECO:0000269|PubMed:22302937"
FT   MUTAGEN         1784
FT                   /note="E->A: Significant reduction in AChR clustering
FT                   ability."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1785
FT                   /note="I->A: Significant reduction in AChR clustering
FT                   ability."
FT                   /evidence="ECO:0000269|PubMed:20566625,
FT                   ECO:0000269|PubMed:22302937"
FT   MUTAGEN         1785
FT                   /note="I->S: Abolishes formation of AGRN-LRP4 complex and
FT                   MUSK activation."
FT                   /evidence="ECO:0000269|PubMed:20566625,
FT                   ECO:0000269|PubMed:22302937"
FT   MUTAGEN         1786
FT                   /note="P->A: Significant reduction in AChR clustering
FT                   ability."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1806
FT                   /note="H->L: No effect on formation of AGRN-LRP4 complex
FT                   nor on MUSK activation."
FT                   /evidence="ECO:0000269|PubMed:22302937"
FT   MUTAGEN         1831
FT                   /note="D->A: Abolishes calcium binding, lowering of binding
FT                   to myotubes and some loss of AChR clustering activity; when
FT                   associated with A-1900."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1876
FT                   /note="R->E: No effect formation of AGRN-LRP4 complex nor
FT                   on MUSK activation."
FT                   /evidence="ECO:0000269|PubMed:22302937"
FT   MUTAGEN         1900
FT                   /note="D->A: Abolishes calcium binding, lowering of binding
FT                   to myotubes and some loss of AChR clustering activity; when
FT                   associated with A-1831."
FT                   /evidence="ECO:0000269|PubMed:20566625"
FT   MUTAGEN         1938
FT                   /note="H->L: No effect formation of AGRN-LRP4 complex nor
FT                   on MUSK activation."
FT                   /evidence="ECO:0000269|PubMed:22302937"
FT   CONFLICT        315..317
FT                   /note="Missing (in Ref. 1; AAA40702)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1761..1767
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1770..1773
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   HELIX           1779..1782
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1800..1812
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1816..1824
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1826..1829
FT                   /evidence="ECO:0007829|PDB:3V65"
FT   STRAND          1832..1838
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1841..1850
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1853..1860
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1863..1865
FT                   /evidence="ECO:0007829|PDB:3V65"
FT   STRAND          1867..1874
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1877..1882
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1888..1891
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1899..1901
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1903..1908
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   HELIX           1921..1923
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   STRAND          1928..1936
FT                   /evidence="ECO:0007829|PDB:3V64"
FT   TURN            1943..1946
FT                   /evidence="ECO:0007829|PDB:3V64"
SQ   SEQUENCE   1959 AA;  208646 MW;  7FEFDFDAFF89CC31 CRC64;
     MPPLPLEHRP RQEPGASMLV RYFMIPCNIC LILLATSTLG FAVLLFLSNY KPGIHFTPAP
     PTPPDVCRGM LCGFGAVCEP SVEDPGRASC VCKKNACPAT VAPVCGSDAS TYSNECELQR
     AQCNQQRRIR LLRQGPCGSR DPCANVTCSF GSTCVPSADG QTASCLCPTT CFGAPDGTVC
     GSDGVDYPSE CQLLSHACAS QEHIFKKFNG PCDPCQGSMS DLNHICRVNP RTRHPEMLLR
     PENCPAQHTP ICGDDGVTYE NDCVMSRIGA TRGLLLQKVR SGQCQTRDQC PETCQFNSVC
     LSRRGRPHCS CDRVTCDGSY RPVCAQDGHT YNNDCWRQQA ECRQQRAIPP KHQGPCDQTP
     SPCHGVQCAF GAVCTVKNGK AECECQRVCS GIYDPVCGSD GVTYGSVCEL ESMACTLGRE
     IQVARRGPCD PCGQCRFGSL CEVETGRCVC PSECVESAQP VCGSDGHTYA SECELHVHAC
     THQISLYVAS AGHCQTCGEK VCTFGAVCSA GQCVCPRCEH PPPGPVCGSD GVTYLSACEL
     REAACQQQVQ IEEAHAGPCE PAECGSGGSG SGEDDECEQE LCRQRGGIWD EDSEDGPCVC
     DFSCQSVPRS PVCGSDGVTY GTECDLKKAR CESQQELYVA AQGACRGPTL APLLPVAFPH
     CAQTPYGCCQ DNFTAAQGVG LAGCPSTCHC NPHGSYSGTC DPATGQCSCR PGVGGLRCDR
     CEPGFWNFRG IVTDGHSGCT PCSCDPRGAV RDDCEQMTGL CSCRPGVAGP KCGQCPDGQV
     LGHLGCEADP MTPVTCVEIH CEFGASCVEK AGFAQCICPT LTCPEANSTK VCGSDGVTYG
     NECQLKAIAC RQRLDISTQS LGPCQESVTP GASPTSASMT TPRHILSKTL PFPHNSLPLS
     PGSTTHDWPT PLPISPHTTV SIPRSTAWPV LTVPPTAAAS DVTSLATSIF SESGSANGSG
     DEELSGDEEA SGGGSGGLEP PVGSIVVTHG PPIERASCYN SPLGCCSDGK TPSLDSEGSN
     CPATKAFQGV LELEGVEGQE LFYTPEMADP KSELFGETAR SIESTLDDLF RNSDVKKDFW
     SVRLRELGPG KLVRAIVDVH FDPTTAFQAS DVGQALLRQI QVSRPWALAV RRPLQEHVRF
     LDFDWFPTFF TGAATGTTAA MATARATTVS RLPASSVTPR VYPSHTSRPV GRTTAPPTTR
     RPPTTATNMD RPRTPGHQQP SKSCDSQPCL HGGTCQDQDS GKGFTCSCTA GRGGSVCEKV
     QPPSMPAFKG HSFLAFPTLR AYHTLRLALE FRALETEGLL LYNGNARGKD FLALALLDGR
     VQFRFDTGSG PAVLTSLVPV EPGRWHRLEL SRHWRQGTLS VDGETPVVGE SPSGTDGLNL
     DTNLYVGGIP EEQVAMVLDR TSVGVGLKGC IRMLDINNQQ LELSDWQRAA VQSSGVGECG
     DHPCLPNPCH GGALCQALEA GMFLCQCPPG RFGPTCADEK SPCQPNPCHG AAPCRVLSSG
     GAKCECPLGR SGTFCQTVLE TAGSRPFLAD FNGFSYLELK GLHTFERDLG EKMALEMVFL
     ARGPSGLLLY NGQKTDGKGD FVSLALHNRH LEFCYDLGKG AAVIRSKEPI ALGTWVRVFL
     ERNGRKGALQ VGDGPRVLGE SPKSRKVPHT MLNLKEPLYI GGAPDFSKLA RGAAVSSGFS
     GVIQLVSLRG HQLLTQEHVL RAVDVSPFAD HPCTQALGNP CLNGGSCVPR EATYECLCPG
     GFSGLHCEKG LVEKSVGDLE TLAFDGRTYI EYLNAVIESE LTNEIPAPET LDSRALFSEK
     ALQSNHFELS LRTEATQGLV LWIGKAAERA DYMALAIVDG HLQLSYDLGS QPVVLRSTVK
     VNTNRWLRIR AHREHREGSL QVGNEAPVTG SSPLGATQLD TDGALWLGGL QKLPVGQALP
     KAYGTGFVGC LRDVVVGHRQ LHLLEDAVTK PELRPCPTP
//
